# A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease

> **NCT04428775** · PHASE2 · TERMINATED · sponsor: **AZTherapies, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** ALZT-OP1a (cromolyn)

## Key facts

- **NCT ID:** NCT04428775
- **Lead sponsor:** AZTherapies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-08
- **Primary completion:** 2021-10-01
- **Final completion:** 2021-10-01
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Low enrollment
- **Last updated:** 2021-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04428775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04428775, "A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04428775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*